Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Angelika Mehnert"'
Um den gesellschaftlichen Nutzen pharmazeutischer Innovationen abzuschätzen, bedarf es adäquater Beurteilungskriterien. Nach einem empirischen Abriß über die Entwicklung der Arzneimittelausgaben erörtern die Autoren die beurteilungsrelevanten ge
Publikováno v:
Current Medical Research and Opinion. 32:147-154
The need to assess relative efficacy in the absence of comparative clinical trials is a problem that is often encountered in economic modeling. The use of matching adjusted indirect comparison (MAIC) in this situation has been suggested. We present t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50a06d1b7ca75e144a9df45f3eb04a72
https://doi.org/10.1185/03007995.2015.1106934
https://doi.org/10.1185/03007995.2015.1106934
Publikováno v:
Journal of Medical Economics. 18:838-849
Triple therapy using a protease inhibitor (PI) with peginterferon and ribavirin (PR) is increasingly used in patients with chronic hepatitis C virus (HCV) infection. The most recently introduced PI, simeprevir (SMV), offers high levels of viral eradi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb23777fbbd963d0cc1bd450a3d991ec
https://doi.org/10.3111/13696998.2015.1044457
https://doi.org/10.3111/13696998.2015.1044457
Autor:
M Pacou, Suzy Van Sanden, Angelika Mehnert, Sophia Ho, Marta Pisini, Vanessa Taieb, Ségolène Pettré, Andrew Ustianowski
Publikováno v:
Journal of Medical Economics. 18:787-796
To conduct a network meta-analysis (NMA) to assess the relative efficacy and safety of simeprevir, a second generation oral protease inhibitor (PI), compared to telaprevir and boceprevir in combination with pegylated interferon-α and ribavirin (PR)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8a3acd2efbf63fa0ac04c7767f4ea73
https://doi.org/10.3111/13696998.2015.1046880
https://doi.org/10.3111/13696998.2015.1046880
Publikováno v:
Journal of Medical Economics. 15:844-861
To model the cost effectiveness of paliperidone palmitate (paliperidone long-acting injectable; PLAI), a new once-monthly long-acting antipsychotic therapy, compared with risperidone long-acting injectable (RLAI) and olanzapine pamoate (OLAI), in mul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::651af1ff617ebed4796e296bfff4e101
https://doi.org/10.3111/13696998.2012.681531
https://doi.org/10.3111/13696998.2012.681531
Publikováno v:
Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen. 104:177-183
Zusammenfassung Eine Anzahl von Veroffentlichungen uber Publikationsbias bzw. selektive Darstellung von Forschungsaktivitaten veranlasst Kritiker, an der Fahigkeit der pharmazeutischen Industrie zu objektiver Forschung zu zweifeln. In dieser Arbeit s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::61fa73594a55e2a44551e799ec9577da
https://doi.org/10.1016/j.zefq.2010.03.011
https://doi.org/10.1016/j.zefq.2010.03.011
Publikováno v:
PharmacoEconomics. 23:49-61
Schizophrenia is one of the most expensive psychiatric conditions because of high direct and indirect costs associated with the nature of the illness, its resistance to treatment and the consequences of relapse. Long-acting risperidone is a new formu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8ddc143439bac67224bc3695369d6a5
https://doi.org/10.2165/00019053-200523001-00005
https://doi.org/10.2165/00019053-200523001-00005
Autor:
Georg Kemmler, Jonathan Rabinowitz, Mariëlle Eerdekens, W. Wolfgang Fleischhacker, Angelika Mehnert
Publikováno v:
British Journal of Psychiatry. 187:131-136
BackgroundThe extent to which antipsychotics improve patients' well-being is uncertain.AimsTo examine psychopathology and patient-rated functioning and well-being in patients treated with risperidone.MethodIn a 1-year, open-label, international multi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21a2e33c8c03253c618305aed5a15eee
https://doi.org/10.1192/bjp.187.2.131
https://doi.org/10.1192/bjp.187.2.131
Autor:
Kathleen Jarboe, Robert A. Lasser, Cynthia A. Bossie, Jean-Pierre Lindenmayer, Young Zhu, Angelika Mehnert
Publikováno v:
International Clinical Psychopharmacology. 20:213-221
Long-acting injectable antipsychotic formulations of conventional antipsychotics were developed to address the problem of partial adherence among patients with schizophrenia. Injection site pain, other skin reactions and patient satisfaction with tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3eefdf693679f04d71a3c72dbb053618
https://doi.org/10.1097/00004850-200507000-00004
https://doi.org/10.1097/00004850-200507000-00004
Publikováno v:
The Journal of Clinical Psychiatry. 65:531-536
Background: We investigated the impact of treatment with long-acting, injectable risperidone versus placebo on health-related quality of life (HRQoL) in patients with schizophrenia. Results are discussed in the context of HRQoL in the general U.S. po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9959f0199d1cb79072e9651e177869e8
https://doi.org/10.4088/jcp.v65n0412
https://doi.org/10.4088/jcp.v65n0412